Abstract 6422: A 3D bioprinted vascularized tumor tissue model of non-small cell lung cancer: A model for drug screening

Abstract Lung cancer remains the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for 80-85% of all cases. There is therefore a need for new, effective treatments for lung cancer. A major challenge in preclinical drug development is the lack of assay platforms that accurately recapitulate the tumor microenvironment (TME), thereby enabling the investigation of cell-cell interactions between the tumor and surrounding stroma cells. To address this gap, we have developed a 3D-bioprinted vascularized lung cancer tissue model in a 96-well format that incorporates human NSCLC cells within a physiologically relevant TME. The TME tissue model includes GFP-expressing lung endothelial cells, pericytes, and fibroblasts that form a vascular network, surrounded by RFP-expressing NSCLC cells (A549, H1975, or H460). Using this platform, we conducted quantitative fluorescence cell imaging to assess vascular morphology, including angiogenesis and tumor growth. Our results revealed distinct tumor morphologies for each of the three NSCLC cell lines used, with H1975 cells showing migration toward the vessels and forming irregular tumor shapes. In contrast, H460 cells formed spheroidal tumors, with no migration to the vessels. We are currently conducting single-cell RNA sequencing on these tissue models and will apply a pharmacogenomics approach to identify novel therapeutic targets based on cancer cell-tumor microenvironment (TME) interactions. This engineered 3D lung cancer model provides a scalable, clinically relevant approach to discovering new treatments for NSCLC patients. Citation Format: Fahimeh Shahabipour, Yuchi Chen, Yen-Ting Tung, Min Jae Song, Marc Ferrer. A 3D bioprinted vascularized tumor tissue model of non-small cell lung cancer: A model for drug screening abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6422.